Barclays 26 (75VM) ニュース

Jq1234, give Bluesky a try. It looks a lot like Twitter did but doesn’t have a controlling algorithm.

With 18 indications trial starting in India well ahead of US trials (and if proven successful) it won't take long when Vivos valuations will be trading forward. IMHO of course. It is worth bios do when efficacy data is strong and potential of approval in the public interest outweighs the risks.

$CTOR Not to many shares left in the market. Should go up real fast when good news comes out. And it should be soon.
Total Insider Shares Held 64.72M
Citius Oncology Annual Shares Outstanding
(Millions of Shares)
2024 68M

Whats 305

You keep pointing to this journal as if that leads to approval. I think i told you this, this journal was meant to explain this garbage trial.....Pointing to the scoreboard. Any approvals? Over 20 years since this trial was started, 6 years since it has ended, and 4.5 years since data lock. NO

Yes I bet it 2x better then before strap in stock-nuts

Anavex Life Sciences Corp. AVXL: This clinical stage biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days. Anavex’s shares gained 63.3% over the last three months compared with the S&P 500’s adva

https://www.otcmarkets.com/filing/html?id=18121280&guid=sJ0-kqxrs0Hhh3h

Bobby, he or she is saying that this is a PIG. I wish you good luck here and I hope you hit it out of the park. As for me I took a huge pounding on this trash but still hold a small position just in case the sky falls out of the universe and this PIG could figure out a way to sell some of their jun

CTOR Not to many shares left in the market. Should go up real fast when good news comes out.
Total Insider Shares Held 64.72M
Citius Oncology Annual Shares Outstanding
(Millions of Shares)
2024 68M

Done. He is an amazing boy. Nuclear engineer.

👇 When he comes through it will be something else for you clowns to talk about!! Sitting around counting days is Sad!!

Recent Open Market purchases by the Chairman of the Board ...David Mott
On December 19, 2024, Mott purchased 213,300 shares at an average price of $4.6722, for a total amount of $996,58034.
On November 13, 2024, he bought 215,868 shares at an average price of $4.6167, totaling $996,59

You don't have to apologize to anybody certainly not me!!!

Family always is first.

Thank him for his Service is the only thing I would ask you to do from me.

$HMBL

I-Glow and Threefight are just two sides of the same coin, it’s just two people bashing and pumping without any actual concrete information and being vague when you ask them for actual proof by saying they heard stuff through the “grapevine” or copy and pasting the same paragraph they have been post

Default occurs when a party does nothing. That is what Megan will do. The SEC will request a default judgment, and it will be granted by the judge.

Megan won't pay up, and that will be the end.

First, this is technically only a guideline addressing FDA staff involved in the approval process. However, the effect of the guidance unavoidably impacts the results for companies submitting NDAs in early AD. That's why all the more formal rulemaking procedural elements are being applied; it's bei

KRTL Holding Group Inc. Announces Milestone Achievement: FDA Registration of Industria Químico Farmaceutica SIGMA CORP. S.R.L.’s Federal Establishment Identifier
January 22, 2025 09:00 ET

Source: KRTL Holding Group

Lakewood, CO, Jan. 22, 2025 (GLOBE NEWSWIRE) --

Inconsequential. The UK decision has to do with Herceptin SC and Mabthera SC. Back then Roche did not file RHUPH20 as an active ingredient early in the process. So the court is saying that they should have done so from the beginning of their filing. Since then everyone has learned their lessons. 

https://media4.giphy.com/media/kIVVupOM0VoW3bNuU7/giphy.gif?cid=6c09b952a8wkvsa7qrmsfrgtjsk2td2p9pidwjk21v4yg2om&ep=v1_internal_gif_by_id&rid=giphy.gif&ct=g